Novo Nordisk CEO: Does Not Rule Out Upgrading to Direct U.S. Stock Listing
nashnova research
Novo Nordisk CEO Mike Doustdar told the Financial Times he is open to upgrading the company's US presence from ADRs to a direct NYSE listing — but has no active plan to do so. The US already accounts for over half of total revenue, and the investor base keeps shifting west.
What is the difference between a direct listing and ADRs?
ADRs — American Depositary Receipts, essentially proxy shares that let foreign companies trade on US exchanges — are how Novo Nordisk currently trades in America. Its primary listing remains on Nasdaq Copenhagen.
A direct listing would give Novo a formal NYSE listing status, making it eligible for inclusion in more US indices and fund mandates.
This means → the core prize is unlocking passive capital. Many US index funds can only buy directly listed stocks.
What exactly did the CEO say?
Doustdar's words: "I'm not the kind of person who immediately says 'no.' I say 'maybe' — tell me the pros and cons, let's discuss."
He confirmed that since taking over as CEO roughly a year ago, there has been no active internal conversation on the topic.
In plain terms = this is a "not opposed, no plan" signal — still a long way from an actual process.
Why is the topic coming up now?
The US generates the majority of Novo's obesity and diabetes drug sales, accounting for over half of total revenue.
Doustdar noted the investor base "has shifted significantly beyond Scandinavia over the past twenty years," with US shareholders steadily gaining share.
Earlier this year, UK pharma giant AstraZeneca completed a direct NYSE listing — providing a peer precedent.
This reflects a shared dilemma among Europe's largest drugmakers: the money and the shareholders are in America, but the listing is still in Europe.
How is Novo Nordisk doing right now?
The stock is down over 20% year-to-date. Market cap sits at roughly $176 billion, far below the $600 billion peak in 2024 when Novo was Europe's most valuable company.
The company has cut about 13,000 jobs over the past year and completed a rebrand last week, dropping "Nordisk" from everyday use.
On Monday it pledged more than five new "multi-blockbuster" drugs by 2030 and signaled openness to more M&A.
How does Novo balance M&A with its Danish roots?
Doustdar struck a disciplined tone on deals: "M&A will continue, but with discipline — we're not going 'Christmas shopping' just because it's fashionable."
He stressed that Novo is "a company of Danish origin that now operates globally," and that its Scandinavian roots remain important.
This means → even if a direct US listing eventually happens, Novo would most likely retain Copenhagen as its primary listing — dual listing, not relocation.
市场有风险，内容仅供研究参考，不构成投资建议。